Immunotherapies for hepatocellular carcinoma

JM Llovet, F Castet, M Heikenwalder… - Nature reviews Clinical …, 2022 - nature.com
Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of …

[HTML][HTML] Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma

S D'souza, KCK Lau, CS Coffin… - World journal of …, 2020 - ncbi.nlm.nih.gov
Chronic infection with viral hepatitis affects half a billion individuals worldwide and can lead
to cirrhosis, cancer, and liver failure. Liver cancer is the third leading cause of cancer …

From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma

Y Fu, S Liu, S Zeng, H Shen - Journal of Experimental & Clinical Cancer …, 2019 - Springer
Hepatocellular carcinoma (HCC) ranks the most common primary liver malignancy and the
third leading cause of tumor-related mortality worldwide. Unfortunately, despite advances in …

Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: a review

K Oura, A Morishita, J Tani, T Masaki - International journal of molecular …, 2021 - mdpi.com
Liver cancer has the fourth highest mortality rate of all cancers worldwide, with
hepatocellular carcinoma (HCC) being the most prevalent subtype. Despite great advances …

Friend or foe? The elusive role of hepatic stellate cells in liver cancer

B Cogliati, CN Yashaswini, S Wang, D Sia… - Nature Reviews …, 2023 - nature.com
Liver fibrosis is a substantial risk factor for the development and progression of liver cancer,
which includes hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma …

Hepatitis B virus-associated hepatocellular carcinoma

GEM Rizzo, G Cabibbo, A Craxì - Viruses, 2022 - mdpi.com
Hepatitis B virus (HBV) is DNA-based virus, member of the Hepadnaviridae family, which
can cause liver disease and increased risk of hepatocellular carcinoma (HCC) in infected …

Tissue CD14+CD8+ T cells reprogrammed by myeloid cells and modulated by LPS

LJ Pallett, L Swadling, M Diniz, AA Maini… - Nature, 2023 - nature.com
The liver is bathed in bacterial products, including lipopolysaccharide transported from the
intestinal portal vasculature, but maintains a state of tolerance that is exploited by persistent …

[HTML][HTML] Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma

Y Cheng, B Gunasegaran, HD Singh, CA Dutertre… - Immunity, 2021 - cell.com
Hepatocellular carcinoma (HCC) often develops following chronic hepatitis B virus (HBV)
infection and responds poorly to immune checkpoint blockade. Here, we examined the …

Engineered T cell therapy for viral and non-viral epithelial cancers

SM Norberg, CS Hinrichs - Cancer Cell, 2023 - cell.com
Engineered T cell therapy has shown remarkable efficacy in hematologic malignancies and
has the potential for application to common epithelial cancers. Diverse T cell therapy …

Targeting human Acyl-CoA: cholesterol acyltransferase as a dual viral and T cell metabolic checkpoint

NM Schmidt, PAC Wing, MO Diniz, LJ Pallett… - Nature …, 2021 - nature.com
Determining divergent metabolic requirements of T cells, and the viruses and tumours they
fail to combat, could provide new therapeutic checkpoints. Inhibition of acyl-CoA: cholesterol …